Four Māori pharmacy students have been awarded Hiwinui Heke pharmacy scholarships – two each from the Auckland and Otago Schools of Pharmacy.
PHARMAC has decided to temporarily list ganciclovir 0.15% eye gel on the Pharmaceutical Schedule from 1 January 2015 until aciclovir 3% eye ointment (Zovirax) supply resumes in New Zealand.
District Health Boards are poised to save more than $100 million over five years as a result of PHARMAC’s expanded role, PHARMAC reports in its Annual Review, released today.
PHARMAC is pleased to announce a decision to widen access to tocilizumab in DHB hospitals from 1 January 2015 for use in patients with severe rheumatoid arthritis who have received inadequate benefit from both a tumour necrosis factor (TNF)-alpha inhibitor (adalimumab or etanercept) and rituximab.
PHARMAC invites proposals for the supply of cleaning services to its offices located at Levels 9, 11, 14 and 15, Simpl House, 40 Mercer Street, Wellington. Closes: 5pm, 22 January 2015.
This letter outlines some clarifications and changes to the 2014/15 Invitation to Tender document, which will be updated on our website and in the eTender system where relevant.
A new agreement for a high cost biologic drug will yield considerable savings for DHBs over the next five years, says PHARMAC.
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2013/14 Invitation to Tender, dated 07 November 2013.
PHARMAC is pleased to announce that we have awarded Hospital Supply Status in DHB hospitals to Janssen-Cilag’s brand of infliximab, Remicade.
PHARMAC is pleased to announce the approval of an agreement with bioCSL (NZ) Ltd for a number of pharmaceuticals (the “Agreement”). This was the subject of a consultation letter dated 24 October 2014.
PHARMAC is pleased to announce the approval of an agreement for the the supply of glyceryl trinitrate oral spray (“Nitrolingual Pump Spray”) and a 25 mg azathioprine tablet (“Azamun”).
PHARMAC will change the way it makes funding decisions from late next year.
PHARMAC is pleased to announce the approval of an agreement with Medtronic New Zealand Limited (“Medtronic”) for the supply of Interventional Cardiology products.
PHARMAC has now completed the review of its decision criteria and is pleased to present the outcome, which is a new framework for PHARMAC’s decision-making.
PHARMAC is seeking feedback on a proposal in relation to the standard supplement oral feed powder, Sustagen Hospital Formula. In summary, PHARMAC is proposing not to increase the community subsidy payable for this product to match the manufacturer’s notified price increase. Closes: Friday, 5 December 2014.
PHARMAC is pleased to announce the award of Sole Subsidised Supply Status in the community, and Hospital Supply Status in DHB hospitals, to Novartis’ brand of fentanyl transdermal patch (Fentanyl Sandoz).
Earlier this year PHARMAC issued a consultation on a proposal to fund melatonin 2 mg modified-release tablets (Circadin) for secondary insomnia in children and adolescents with neurodevelopmental disorders from 1 July 2014. Since we originally consulted on the melatonin funding proposal in May 2014 our budget position has changed. This means that PHARMAC is not in a position to invest in melatonin during the current financial year.
PHARMAC is seeking feedback on a proposal to widen access to tocilizumab in DHB hospitals from 1 January 2015. Closes: Thursday, 27 November 2014.
PHARMAC is seeking feedback on a proposal to list a range of interventional cardiology products supplied by Terumo Australia Pty Ltd (“Terumo”) in Part III of Section H of the Pharmaceutical Schedule from 1 February 2015. Closes: Tuesday, 2 December 2014.
PHARMAC is interested in receiving information from suppliers and wholesalers who are interested in pursuing a listing agreement with PHARMAC for the supply of adrenaline auto-injectors in the community and DHB hospitals. Closes: Monday, 1 December 2014.